Chancery Won't Pause Vaxart Insider-Trading Suit In Del.
Citing Delaware's stronger interest in judging corporate law breach claims tied to a more than $200 million insider-trading scheme involving biotech firm Vaxart Inc., a Delaware Chancery Court judge refused Monday...To view the full article, register now.
Already a subscriber? Click here to view full article